Alkem Laboratories Stock in Focus Following DCGI Approval for Semaglutide Injection

Alkem Laboratories Receives DCGI Approval for Semaglutide Injection

On March 23, the share price of Alkem Laboratories will remain in focus following the company's receipt of approval from the Drug Controller General of India (DCGI) to manufacture and market Semaglutide Injection in India.

Alkem has launched its semaglutide pre-filled disposable injection pen, priced at Rs 1,800 for a month's dosage, translating to a weekly cost of Rs 450. Additionally, the company is offering a reusable injection pen for semaglutide administration for higher maintenance doses.

The DCGI approval for manufacturing and marketing semaglutide was granted for the treatment of type 2 diabetes mellitus and chronic weight management, following a review of Phase 3 clinical trials conducted in India. The company has launched semaglutide injection in India under the brand names "Semasize", "Obesema", and "Hepaglide".

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Alkem has also received a 'Certificate of GMP Compliance of a Manufacturer' from the Malta Medicines Authority for its manufacturing facility located at Daman, India, valid for a period of three years from December 9, 2025. Additionally, the Department of Pharmacy (Human Medicines) - Germany has issued a similar certificate to the company's manufacturing facility located at Baddi, India, valid for three years from an unspecified date in the current month.